Category «Cancer treatment Canada»

Astrazeneca canada release canada denies public use of potentially existence prolonging ovarian cancer treatment lynparza olaparib

Pan-Canadian Oncology Drug Review (pCODR) Decides to not Recommend Lynparza for Reimbursement MISSISSAUGA, ON, March. 5, 2016 /CNW/ – Following its deliberations, the pan-Canadian Oncology Drug Review (pCODR) lately announced its decision to not recommend for provincial reimbursement, Lynparza (olaparib), a maintenance strategy to women with platinum-sensitive relapsed BRCA-mutated (germline or somatic) high quality serous …